Breaking Finance News

A statement released earlier today by Oddo Seydler Bank AG about EVOTEC (ETR:EVT) bumps the target price to 5.60EUR

Just yesterday EVOTEC (ETR:EVT) traded 0.45% higher at 5.01EUR. EVOTEC’s 50-day moving average is 20.60EUR and its 200-day moving average is 20.20EUR. The last stock price is down -0.24% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 146,774 shares of EVT traded hands, up from an average trading volume of 130,103

Oddo Seydler Bank AG upped the price target of EVOTEC (ETR:EVT) to 5.60EUR reporting a possible upside of 0.12%.

Previously on 9/22/2016, Bankhaus Lampe KG released a statement about EVOTEC (ETR:EVT) increased the target price from 0.00EUR to 5.40EUR. At the time, this indicated a possible upside of 0.13%.

Recent Performance Chart


EVOTEC has 52 week low of 16.37EUR and a 52 week high of 21.25EUR and has a market capitalization of 0 EUR.

Brief Synopsis On EVOTEC (ETR:EVT)

Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator's targets and programs. EVT Innovate focuses on developing its internal assets, including early-stage discovery programs, as well as drug candidates. The Company focuses on therapeutic areas, including central nervous system (CNS)/neurology, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. Its clinical products include EVT302, EVT201, EVT100 and EVT401. Its pre-clinical products include EVT770, EVT801, EVT701 and EVT601. EVT302 is an inhibitor of monoamine oxidase type B (MAO-B), an enzyme that breaks down the chemical messenger dopamine in the brain and contributes to the production of free radicals.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *